Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study show encouraging signals in acute MS lesions, according to a recent article. The novel imaging technique aims to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, potentially offering a more precise way to measure myelin loss and repair.
These findings have direct implications for Lucid-MS, the company's investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.
The study's progress is a significant milestone for Quantum BioPharma, which is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
In addition to its MS research, Quantum BioPharma invented unbuzzd and spun out its OTC version to a company, Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 19.84% of UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company's newsroom at https://nnw.fm/QNTM. The full article can be viewed at https://nnw.fm/fsDHa.
